BioSig Technologies, Inc. Overview
Pro stress-test →BioSig Technologies is a medical technology company that provides digital signal processing technology platform services, specifically the PURE EP Platform which delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias. As a commercial-stage medical device company, it has developed a breakthrough technology platform that revolutionizes how intracardiac electrical signals are captured and analyzed.
Strategic Profile
Pro stress-test →The PURE EP Platform is an FDA-cleared, non-invasive Class II device engineered to overcome the limitations of traditional electrophysiology tools by providing significantly enhanced signal detection capabilities. The company has a research agreement with Mayo Foundation with the right to sublicense for patent applications in signal processing, physiologic recording, electrophysiology recording, electrophysiology software, and autonomics.
Competitive Landscape
Pro stress-test →BioSig operates in the highly specialized medical devices electrophysiology segment valued in billions, with revenue targeted at healthcare institutions, cardiac ablation centers, and electrophysiology labs. The company competes with established cardiac mapping and ablation system providers (Biosense Webster, St. Jude Medical, Medtronic) but differentiates through proprietary digital signal processing technology.
Industry Context
BioSig Technologies, Inc. operates in Medical Devices - Electrophysiology / Cardiac Ablation Systems.
Key facts
Founded: 2009 · Headquarters: Los Angeles, United States · Revenue: $0.04M (2024) · Market cap: $216M